25.91

0.32% 0.10

Arcutis Biotherapeutics Inc (ARQT)

Overview News Price History Option Chain Financials Why ARQT Down? Discussions Forecast

Arcutis Biotherapeutics Inc stock is traded at $25.91, with a volume of 756.10K. It is up +0.32% in the last 24 hours and up +21.97% over the past month. Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Previous Close:

$25.81

Open:

$25.84

24h Volume:

756.10K

Relative Volume:

0.45

Market Cap:

$3.24B

Revenue:

$415.62M

Net Income/Loss:

$-2.38M

P/E Ratio:

-912.32

EPS:

-0.0284

Net Cash Flow:

$16.92M

1W Performance:

-3.24%

1M Performance:

+21.97%

6M Performance:

-11.39%

1Y Performance:

+87.36%

1-Day Range:

$25.25

$26.12

1-Week Range:

$25.25

$27.20

52-Week Range:

$13.06

$31.77

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Name

Arcutis Biotherapeutics Inc

Sector

Healthcare (1097)

Industry

Biotechnology (615)

Phone

805-418-5006

Address

3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA

Employee

354

Twitter

@ArcutisBio

Next Earnings Date

2026-08-05

Latest SEC Filings

ARQT's Discussions on Twitter

Compare ARQT vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ARQT Arcutis Biotherapeutics Inc	25.87	3.28B	415.62M	-2.38M	16.92M	-0.0284
VRTX Vertex Pharmaceuticals Inc	528.26	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	647.63	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	926.39	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.74	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.28	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-25-25	Initiated	Goldman	Neutral
Dec-30-24	Initiated	H.C. Wainwright	Buy
Aug-28-24	Initiated	Jefferies	Buy
Jan-03-24	Upgrade	Mizuho	Neutral → Buy
Oct-26-23	Downgrade	Mizuho	Buy → Neutral
Oct-13-23	Downgrade	Goldman	Buy → Neutral
Sep-07-22	Initiated	Needham	Buy
Mar-17-22	Initiated	Goldman	Buy
Jun-30-21	Initiated	Mizuho	Buy
May-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-09-20	Upgrade	Goldman	Neutral → Buy
Oct-08-20	Initiated	Truist	Buy
Feb-25-20	Initiated	Cantor Fitzgerald	Overweight
Feb-25-20	Initiated	Cowen	Outperform
Feb-25-20	Initiated	Goldman	Neutral
Feb-25-20	Initiated	Guggenheim	Buy

View All

Arcutis Biotherapeutics Inc Stock (ARQT) Latest News

Jun 30, 2026

Arcutis launches virtual dermatology platform for skin conditions By Investing.com - Investing.com India

Jun 30, 2026

Arcutis Launches Virtual Dermatology Platform to Boost Access to Roflumilast - The Dermatology Digest

Jun 30, 2026

Avoiding Lag: Real-Time Signals in (ARQT) Movement - Stock Traders Daily

Jun 30, 2026

Arcutis launches virtual dermatology platform for skin conditions - Investing.com

Jun 30, 2026

Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications - The Manila Times

Jun 30, 2026

Arcutis’ new virtual dermatology platform targets care gaps for 45M Americans - Stock Titan

Jun 30, 2026

FDA approves Zoryve cream for plaque psoriasis in children age 2+ By Investing.com - Investing.com India

Jun 30, 2026

Jun 29, 2026

Arcutis Biotherapeutics (ARQT) Secures FDA Approval for ZORYVE C - GuruFocus

Jun 29, 2026

FDA approves Zoryve cream for plaque psoriasis in children age 2+ - Investing.com South Africa

Jun 29, 2026

Arcutis Biotherapeutics Announces FDA Approval of Expanded ZORYVE Cream 0.3% Indication for Children With Plaque Psoriasis Down to Age 2 - Quiver Quantitative

Jun 29, 2026

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2 - GlobeNewswire Inc.

Jun 29, 2026

Jun 28, 2026

Arcutis Biotherapeutics (ARQT) Edges Higher as Bullish Momentum BuildsBreakout Trade - dars.gov.et

Jun 28, 2026

Jun 26, 2026

A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $36 - Moomoo

Jun 26, 2026

Jun 25, 2026

Arcutis Biotherapeutics Inc Actuals & Estimates (NASDAQ:ARQT) - TradingView

Jun 25, 2026

ARQT Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 23, 2026

Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65% - The Globe and Mail

Jun 23, 2026

Jun 22, 2026

Arcutis Biotherapeutics Inc (NASDAQ:ARQT): A GARP Growth Play at a Reasonable Price - ChartMill

Jun 22, 2026